Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 0.33 + web  Related to the article below (Last Update: 8/4/2008)

Web.com Reports Second Quarter 2008 Financial Results
istockAnalyst.com, OR -
"Despite challenging economic conditions, Web.com was able to hit the top of its quarterly revenue and earnings guidance. The operating leverage potential ...
Puget Energy Reports Second Quarter 2008 Financial Results
WELT ONLINE, Germany -
Second Quarter 2007 EPS Reconciliation Cents per diluted share Puget Energy?s second quarter 2007 earnings from PSE $ 0.33 Increase in natural gas margin ...PSD
Prophecy drills 45.5 metres of 0.33% copper and 0.003% Molybdenum ...
Canada NewsWire (press release), Canada - Jul 28, 2008
For further information: about Prophecy, please visit our web site at www.prophecyresource.com or contact us toll-free at (888) 818-8748.CVE:PCY - TSE:X - CVE:ETF

Earthtimes (press release)
Plum Creek Timber Company, Inc. Reports Results for Second Quarter ...
MarketWatch - Jul 28, 2008
A live webcast of the conference call may be accessed through Plum Creek's Web site at www.plumcreek.com by clicking on the "Investors" link. ...
Stratasys Reports Record Second Quarter Financial Results Trading Markets (press release)
EFI Reports Q2 2008 Results MarketWatch
all 1,378 news articles »  SSYS - PCL - EFII

WELT ONLINE
Aladdin Knowledge Systems Reports Second Quarter 2008 Financial ...
MarketWatch - Jul 21, 2008
Released Aladdin eSafe v6.2 Proxy, offering organizations more options in control and flexibility for secure Web gateway deployment. ...
Leadis Technology Reports Second Quarter 2008 Results MarketWatch
all 773 news articles »  LDIS - ALDN

Earthtimes (press release)
Peapack-Gladstone Financial Corporation Reports 27% Increase in ...
MarketWatch - Aug 1, 2008
To learn more about Peapack-Gladstone Financial Corporation and its services please visit our web site at www.pgbank.com or call 908-234-0700. ...
Bank of Hawaii Corporation Second Quarter 2008 Financial Results Trading Markets (press release)
Greene County Bancorp, Inc. Announces Earnings Increase MarketWatch
all 1,059 news articles »  GCBC - BOH - PGC
Waddell & Reed Financial, Inc. Reports Second Quarter Results
MarketWatch - Jul 29, 2008
Live access to the teleconference will be available on the "Corporate" section of our Web site at http://www.waddell.com. A Web cast replay will be made ...WDR
American Equity Reports Second Quarter 2008 Operating Income of ...
WELT ONLINE, Germany - Jul 30, 2008
An audio replay will be available shortly after the call on AEL?s web site. An audio replay will also be available via telephone through August 21, ...AEL
Digital River Announces Second Quarter Financial Results
MarketWatch - Jul 30, 2008
A webcast replay of the call will be archived on Digital River's corporate Web site. Digital River, Inc., a leading provider of global e-commerce solutions, ...DRIV
Kaboose Reports Record Second Quarter 2008 Results with Revenue ...
Canada NewsWire (press release), Canada - Jul 31, 2008
The webcast will be archived on the same web page for 30 days following the live call. The second quarter financial statements and related management's ...TSE:KAB - BOM:532354 - GIS
Source: Google News

Measuring the Independence of Central Banks and Its Effect on Policy Outcomes -
A Cukierman, SB Web, B Neyapti - The World Bank Economic Review, 1992 - World Bank
... 0.50 Unconditional dismissal possible by legislature 0.33 At executive's discretion
0.17 ... 0.67 Bank only advises government 0.33 Bank has no say 0.00 ...

Creating Adaptive Web Sites Through Usage-Based Clustering of URLs -
B Mobasher, R Cooley, J Srivastava - Proceedings of the 1999 Workshop on Knowledge and Data …, 1999 - doi.ieeecs.org
... In this paper we have presented an architecture for automatic Web personalization
based on Web usage data. ... research/mmdbms 0.34 /research/agassiz 0.33 ...

SILK MEDIATED DEFENSE BY AN ORB WEB SPIDER AGAINST PREDATORY MUD-DAUBER WASPS -
TA Blackledge, JW Wenzel - Behaviour, 2001 - Springer
... Sceliphron Enclosure 1 2 nd web 0.33 (12) 1.00 (2) Enclosure 2 2 nd web 0.00 (8) **
Chalybion 2 nd web 0.18 (28) 0.30 (33) 3 rd web 0.00 (14) 0.33 (15) ...

Web development: estimating quick-to-market software -
DJ Reifer, RC Inc - Software, IEEE, 2000 - ieeexplore.ieee.org
... Business-to-business applications 2.0 1.5 1.00 * Web-based information utilities
2.1 2.0 1.00 * * Either 0.5 or 0.33 depending on the scaling (>40 Web Objects) ...

[PDF] Mapping networks of terrorist cells -
VE Krebs - Connections, 2002 - insna.org
... 52 http://www.sfu.ca/insna/Connections-Web/Volume24-3/Valdis.Krebs.web.pdf ? 2002 ...
1.00 1.00 0.00 0.33 0.00 1.00 0.33 0.33 0.00 1.00 0.67 0.33 0.00 0.27 0.33 ...

The calculation of web impact factors -
P Ingwersen - Journal of Documentation, 1998 - ingentaconnect.com
... 4. Academic (.edu) 0.807 0.47 0.33 ?0.57 ?2.2 5,390,097 ... If the figures from the mainly
US web sectors are calculated together and taken as the current ...

[PDF] … importance and trophic role of heterotrophic dinoflagellates in a coastal pelagial food web -
PJ Hansen - Mar. Ecol. Prog. Ser, 1991 - int-res.com
... food web ... 0.33 to 1 O/O). The cells in at least 50 m1 were allowed to sediment and
the flagellates iden- tified and counted with an inverted microscope. ...

Variation in d 15 N and d 13 C trophic fractionation: implications for aquatic food web studies -
MJ Vander Zanden, JB Rasmussen - Limnology and Oceanography, 2001 - JSTOR
... 0.045 ' Nbaseline +0.55%0? +0.16 Minagawa and Wada (1984): +0.49%o +0.33 Pooled
sources ... web to be comprised of five trophic links, which is a con- servative ...

[PDF] Human Performance on Clustering Web Pages -
SA Macskassy, A Banerjee, BD Davison, H Hirsh - Proceedings of ACM SIGKDD International Conference on …, 1998 - athos.rutgers.edu
... Overall .12 .58 0.33 0.32 .13 .59 0.36 0.35 ... work began as an off-shoot of our
observation that it was difficult to build a system that clustered web pages when ...

… new entry to web page table upon receiving web page including link to another web page not having … -
LM Monier - US Patent 5,974,455, 1999 - freepatentsonline.com
... Network latency thus also tends to limit the number Web pages that can be processed
by prior art Web crawlers to about 0.33 Web pages per second. ...

Source: Google Scholar
 
 

Genmab Announces Early Results Of Ongoing HuMax-CD4 Trials

Article Date: 11 Dec 2006 - 0:00am (PST)
Genmab A/S (CSE: GEN) announced today positive early results of the first stage of the ongoing pivotal Phase III study of HuMax-CD4(R) (zanolimumab) in cutaneous T-cell lymphoma (CTCL) and the ongoing Phase II study in non-cutaneous T-cell lymphoma (NCTCL). In the pivotal CTCL study, clinical response was shown in 5 of 12 patients (42%) in the two highest dose groups. A partial response was obtained by 1 of 6 patients (16%) in the 8 mg/kg dose group and 4 of 6 patients (67%) in the 14 mg/kg dose group. Patients were also treated at the 4 mg/kg dose level, with no responses observed. This dose level is not being used in the second part of the ongoing pivotal study.

A total of 22 patients were enrolled in three dose cohorts in the first part of the pivotal study and received infusions of 4, 8, or 14 mg/kg of HuMax-CD4 once weekly for 12 weeks. Patients were evaluated 4 and 8 weeks after the final treatment dose and every 8 weeks until progression of disease. The goal of this first portion of the Phase III study was to characterize material obtained from a new manufacturing site.

Article continues below and (thank you)
 
"We have successfully characterized the new HuMax-CD4 material and have moved into the second phase of the CTCL pivotal study," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "We are encouraged by the response rates in these patients who have failed other therapies."

Preliminary results in the ongoing Phase II clinical trial in HuMax-CD4 to treat non-cutaneous T-cell lymphoma (NCTCL) showed that 4 of 14 patients (28.5%) had objective responses. Plans are ongoing to next test HuMax-CD4 in combination with chemotherapy for the NCTCL patients.

Results from both studies will be presented at the 48th American Society of Hematology Annual Meeting and Exposition in Orlando, Florida December 9-12, 2006.

The preliminary HuMax-CD4 CTCL Phase III results are being presented at poster session #2731 on December 10 from 9AM to 8PM local time in Hall E1, board 909. The preliminary NCTCL results are being presented in poster session #2723 on December 10, from 9AM to 8PM local time in Hall E1, board 901.

About CTCL and NCTCL

Cutaneous T-cell lymphomas are a group of lymphomas characterized by abnormal accumulation of malignant T-cells in the skin, potentially resulting in the development of rashes, plaques and tumors. The most common types of CTCL include mycosis fungoides (MF) and Sezary syndrome (SS). CTCL result from errors in the production of T-lymphocytes or transformation of T- lymphocytes into malignant cells. Abnormal, uncontrolled growth and multiplication of malignant T-lymphocytes result in accumulation of these lymphocytes in the skin and may in some cases spread and affect the lymph nodes and other body tissues and organs, resulting in life-threatening complications.

Non-cutaneous T-cell lymphomas (NCTCL) are defined by highly malignant disease, which has localized to the lymph nodes even at the earliest stage of the disease, and include angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma and unspecified peripheral T-cell lymphoma. NCTCL is characterized by aggressive progression with average survival time of approximately two years.

About HuMax-CD4 (zanolimumab)

HuMax-CD4 is a human monoclonal antibody currently in Phase III development for cutaneous T-cell lymphoma (CTCL) and in Phase II for non- cutaneous T-cell lymphoma. These types of lymphomas express the CD4 receptor, which is the target of HuMax-CD4. In April 2005, Genmab and the United States Food and Drug Administration (FDA) reached an agreement on the design of its pivotal study protocol for HuMax-CD4 to treat CTCL under the Special Protocol Assessment process (SPA). The pivotal study includes patients with MF who are refractory to or intolerant of Targretin(R) and one other standard therapy, and will treat a total of 88 patients.

In March 2004, Genmab announced that HuMax-CD4 had been designated a Fast Track Product by the US Food and Drug Administration (FDA). This designation covers patients with CTCL for whom no available therapy exists, i.e. have failed at least two systemic treatment regimens. HuMax-CD4 for the treatment of MF has also been granted Orphan Drug status in the US and Europe. HuMax- CD4 is being developed under a collaboration with Serono.

About Genmab A/S

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche and Amgen. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(R) platform for the rapid creation and development of human antibodies to virtually any disease target. In addition, Genmab has developed UniBody(TM), a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Copenhagen, Denmark, Utrecht, the Netherlands, Princeton, New Jersey, US and Hertfordshire in the United Kingdom. For more information about Genmab, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax- EGFr(TM); HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM), HuMax-CD38(TM); and UniBody(TM) are all trademarks of Genmab A/S.

UltiMAb(R) is a trademark of Medarex, Inc.

Genmab
http://www.genmab.com
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page